Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data

被引：16

作者：

Wanlapakorn, Nasamon ^{[1
]}

Suntronwong, Nungruthai ^{[1
]}

Phowatthanasathian, Harit ^{[1
]}

Yorsaeng, Ritthideach ^{[1
]}

Thongmee, Thanunrat ^{[1
]}

Vichaiwattana, Preeyaporn ^{[1
]}

Auphimai, Chompoonut ^{[1
]}

Wongsrisang, Lakkhana ^{[1
]}

Klinfueng, Sirapa ^{[1
]}

Sudhinaraset, Natthinee ^{[1
]}

Poovorawan, Yong ^{[1
,2
]}

机构：

[1] Chulalongkorn Univ, Fac Med, Ctr Excellence Clin Virol, Bangkok, Thailand

[2] Royal Soc Thailand, FRS T, Bangkok, Thailand

来源：

VACCINE | 2022年 / 40卷 / 23期

关键词：

Heterologous; Vaccine; CoronaVac; AZD1222; COVID-19; EFFICACY;

D O I：

10.1016/j.vaccine.2022.04.043

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Limited data are available on the responses to heterologous vaccine regimens for SARS-CoV-2, especially among countries using inactivated and adenoviral-vectored vaccines. A total of 77 participants who received heterologous inactivated COVID-19 vaccine (CoronaVac) and adenoviral-vectored vaccine (AZD1222) were enrolled in our study. There were two comparison groups vaccinated with the homologous CoronaVac (N = 79) and AZD1222 (N = 78) regimen. All sera samples were tested for anti-receptor binding-domain IgG (anti-RBD IgG) using a chemiluminescent microparticle immunoassay (CMIA). The neutralizing activity in a subset of serum samples was tested against the original Wuhan strain and variants of concern, B.1.1.7, B.1.617.2 and B.1.351, using an enzyme-linked immunosorbent assay (ELISA)based surrogate virus neutralization test (sVNT). The heterologous CoronaVac/AZD1222 vaccine induced higher levels of anti-RBD IgG than that of two-dose homologous CoronaVac or AZD1222 vaccines (p < 0.001). Sera samples of the CoronaVac/AZD1222 vaccine recipients elicited higher neutralizing antibody activity against the original Wuhan and all variants of concern than in the recipients of the two-dose CoronaVac. The heterologous CoronaVac followed by AZD1222 is an alternative regimen to combat with the SARS-CoV-2 variants in case of vaccine shortage with improved immunogenicity compared to the homologous CoronaVac regimen. (c) 2022 Elsevier Ltd. All rights reserved.

引用

页码：3203 / 3209

页数：7

共 24 条

[1] Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination [J].

Barros-Martins, Joana ;

Hammerschmidt, Swantje, I ;

Cossmann, Anne ;

Odak, Ivan ;

Stankov, Metodi, V ;

Ramos, Gema Morillas ;

Dopfer-Jablonka, Alexandra ;

Heidemann, Annika ;

Ritter, Christiane ;

Friedrichsen, Michaela ;

Schultze-Florey, Christian ;

Ravens, Inga ;

Willenzon, Stefanie ;

Bubke, Anja ;

Ristenpart, Jasmin ;

Janssen, Anika ;

Ssebyatika, George ;

Bernhardt, Gunter ;

Muench, Jan ;

Hoffmann, Markus ;

Poehlmann, Stefan ;

Krey, Thomas ;

Bosnjak, Berislav ;

Foerster, Reinhold ;

Behrens, Georg M. N. .

NATURE MEDICINE, 2021, 27 (09) :1525-+

[2] Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial [J].

Borobia, Alberto M. ;

Carcas, Antonio J. ;

Perez-Olmeda, Mayte ;

Castano, Luis ;

Jesus Bertran, Maria ;

Garcia-Perez, Javier ;

Campins, Magdalena ;

Portoles, Antonio ;

Gonzalez-Perez, Maria ;

Garcia Morales, Maria Teresa ;

Arana-Arri, Eunate ;

Aldea, Marta ;

Diez-Fuertes, Francisco ;

Fuentes, Inmaculada ;

Ascaso, Ana ;

Lora, David ;

Imaz-Ayo, Natale ;

Baron-Mira, Lourdes E. ;

Agusti, Antonia ;

Perez-Ingidua, Carla ;

Gomez de la Camara, Agustin ;

Ramon Arribas, Jose ;

Ochando, Jordi ;

Alcami, Jose ;

Belda-Iniesta, Cristobal ;

Frias, Jesus .

LANCET, 2021, 398 (10295) :121-130

[3] Immunosenescence and human vaccine immune responses [J].

Crooke, Stephen N. ;

Ovsyannikova, Inna G. ;

Poland, Gregory A. ;

Kennedy, Richard B. .

IMMUNITY & AGEING, 2019, 16 (01)

[4]

European Medicines Agency, 2021, Newsroom

[5] A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: An interim analysis in Indonesia [J].

Fadlyana, Eddy ;

Rusmil, Kusnandi ;

Tarigan, Rodman ;

Rahmadi, Andri Reza ;

Prodjosoewojo, Susantina ;

Sofiatin, Yulia ;

Khrisna, Citra, V ;

Sari, Rini Mulia ;

Setyaningsih, Lilis ;

Surachman, Fikrianti ;

Bachtiar, Novilia Sjafri ;

Sukandar, Hadyana ;

Megantara, Imam ;

Murad, Chrysanti ;

Pangesti, Krisna Nur A. ;

Setiawaty, Vivi ;

Sudigdoadi, Sunarjati ;

Hu, Yaling ;

Gao, Qiang ;

Kartasasmita, Cissy B. .

VACCINE, 2021, 39 (44) :6520-6528

[6] Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection [J].

Feng, Shuo ;

Phillips, Daniel J. ;

White, Thomas ;

Sayal, Homesh ;

Aley, Parvinder K. ;

Bibi, Sagida ;

Dold, Christina ;

Fuskova, Michelle ;

Gilbert, Sarah C. ;

Hirsch, Ian ;

Humphries, Holly E. ;

Jepson, Brett ;

Kelly, Elizabeth J. ;

Plested, Emma ;

Shoemaker, Kathryn ;

Thomas, Kelly M. ;

Vekemans, Johan ;

Villafana, Tonya L. ;

Lambe, Teresa ;

Pollard, Andrew J. ;

Voysey, Merryn .

NATURE MEDICINE, 2021, 27 (11) :2032-+

[7] Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study [J].

Hillus, David ;

Schwarz, Tatjana ;

Tober-Lau, Pinkus ;

Vanshylla, Kanika ;

Hastor, Hana ;

Thibeault, Charlotte ;

Jentzsch, Stefanie ;

Helbig, Elisa T. ;

Lippert, Lena J. ;

Tscheak, Patricia ;

Schmidt, Marie Luisa ;

Riege, Johanna ;

Solarek, Andre ;

von Kalle, Christof ;

Dang-Heine, Chantip ;

Gruell, Henning ;

Kopankiewicz, Piotr ;

Suttorp, Norbert ;

Drosten, Christian ;

Bias, Harald ;

Seybold, Joachim ;

Klein, Florian ;

Kurth, Florian ;

Corman, Victor Max ;

Sander, Leif Erik .

LANCET RESPIRATORY MEDICINE, 2021, 9 (11) :1255-1265

[8] COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants [J].

Jalkanen, Pinja ;

Kolehmainen, Pekka ;

Hakkinen, Hanni K. ;

Huttunen, Moona ;

Tahtinen, Paula A. ;

Lundberg, Rickard ;

Maljanen, Sari ;

Reinholm, Arttu ;

Tauriainen, Sisko ;

Pakkanen, Sari H. ;

Levonen, Iris ;

Nousiainen, Arttu ;

Miller, Taru ;

Valimaa, Hanna ;

Ivaska, Lauri ;

Pasternack, Arja ;

Naves, Rauno ;

Ritvos, Olli ;

Osterlund, Pamela ;

Kuivanen, Suvi ;

Smura, Teemu ;

Hepojoki, Jussi ;

Vapalahti, Olli ;

Lempainen, Johanna ;

Kakkola, Laura ;

Kantele, Anu ;

Julkunen, Ilkka .

NATURE COMMUNICATIONS, 2021, 12 (01)

[9]

Li J, 2021, medRxiv, DOI DOI 10.1101/2021.09.03.21263062

[10] Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial [J].

Liu, Xinxue ;

Shaw, Robert H. ;

Stuart, Arabella S. V. ;

Greenland, Melanie ;

Aley, Parvinder K. ;

Andrews, Nick J. ;

Cameron, J. Claire ;

Charlton, Sue ;

Clutterbuck, Elizabeth A. ;

Collins, Andrea M. ;

Dinesh, Tanya ;

England, Anna ;

Faust, Saul N. ;

Ferreira, Daniela M. ;

Finn, Adam ;

Green, Christopher A. ;

Hallis, Bassam ;

Heath, Paul T. ;

Hill, Helen ;

Lambe, Teresa ;

Lazarus, Rajeka ;

Libri, Vincenzo ;

Long, Fei ;

Mujadidi, Yama F. ;

Plested, Emma L. ;

Provstgaard-Morys, Samuel ;

Ramasamy, Maheshi N. ;

Ramsay, Mary ;

Read, Robert C. ;

Robinson, Hannah ;

Singh, Nisha ;

Turner, David P. J. ;

Turner, Paul J. ;

Walker, Laura L. ;

White, Rachel ;

Nguyen-Van-Tam, Jonathan S. ;

Snape, Matthew D. .

LANCET, 2021, 398 (10303) :856-869

← 1 2 3 →